CGEM · Company research
Cullinan Therapeutics, Inc. Common Stock (CGEM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Raised to Hold at Wall Street Zen - MarketBeat | Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Raised to Hold at Wall Street Zen MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| Cullinan doses first patient in CLN-049 Phase 2 AML study | CGEM Stock News - Stock Titan | Cullinan doses first patient in CLN-049 Phase 2 AML study | CGEM Stock News Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (CGEM) Ticks Higher: Shares Gain 1.31% to $16.25 - Elliott Wave Count - https://www.siam.in/ | Cullinan Therapeutics (CGEM) Ticks Higher: Shares Gain 1.31% to $16.25 - Elliott Wave Count https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 7, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price - Simply Wall Street | Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued? - Simply Wall Street | Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up - Here's What Happened - MarketBeat | Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up - Here's What Happened MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| Cullinan Management Advances NDA for Zipalertinib Combination - The Globe and Mail | Cullinan Management Advances NDA for Zipalertinib Combination The Globe and Mail | View source ↗ | The Globe and Mail | Oct 3, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat | Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program | Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program | Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| CGEM Stock Price, Quote & Chart - ChartMill | CGEM Stock Price, Quote & Chart ChartMill | View source ↗ | ChartMill | Oct 1, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Yahoo Finance | Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 Yahoo Finance | View source ↗ | Yahoo Finance | Sep 26, 2026 | neutral | 0 | 0.6 |
| CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits | CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger Stocktwits | View source ↗ | Stocktwits | Sep 24, 2026 | neutral | 0 | 0.6 |
| $CGEM stock is down 20% today. Here's what we see in our data. - Quiver Quantitative | $CGEM stock is down 20% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan | Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan Stock Titan | View source ↗ | Stock Titan | Sep 10, 2026 | neutral | 0 | 0.6 |
| CGEM Forecast — Price Target — Prediction for 2027 - TradingView | CGEM Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha | Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 11, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.